Warning Letter — Lovelace Biomedical Research Institute
The FDA issued a Warning Letter to the Lovelace Biomedical Research Institute following an inspection by the Center for Drug Evaluation and Research (CDER).
This affects the Lovelace Biomedical Research Institute, its clinical and preclinical research staff, and sponsors utilizing their research services.
A CDER-issued Warning Letter to a research institute typically indicates significant deviations from regulatory standards, such as Good Laboratory Practice (GLP) or clinical investigator requirements. This may lead to increased scrutiny of data submitted by the institute to support drug applications and could necessitate remediation of internal quality systems.
Review current Good Laboratory Practice (GLP) or clinical trial oversight protocols to ensure documentation and data integrity standards meet CDER expectations. Conduct internal audits of recent study data to verify consistency between raw observations and final reports.
FDA Warning Letter issued to: Lovelace Biomedical Research Institute. 10/06/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovelace-biomedical-research-institute-725136-10062026
Open in openFDA / FDA.gov